Patents by Inventor Marko Salmi
Marko Salmi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10526607Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.Type: GrantFiled: March 25, 2014Date of Patent: January 7, 2020Assignee: FARON PHARMACEUTICALS OYInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Patent number: 10247730Abstract: This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favorable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favorable change or starts to show an unfavorable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS.Type: GrantFiled: January 22, 2014Date of Patent: April 2, 2019Assignee: FARON PHARMACEUTICALS OYInventors: Mikael Maksimow, Marko Salmi, Markku Jalkanen, Sirpa Jalkanen
-
Patent number: 9238550Abstract: Conveyor beam for a conveyor system, comprising a plurality of connector elements and at least two conveyor beam elements, where the connector element comprises a central portion, two outer portions and two peripherally grooves extending peripherally around the connector element between the central portion and the outer portions, where the connector element is provided with a first inserting position in which the connector element is inserted between two conveyor beam elements with the first outer portion positioned in a channel of a first conveyor beam element and the second outer portion positioned in a channel of a second conveyor beam elements, and a second arresting position, in which the connector element locks the conveyor beam elements together to form the conveyor beam. The advantage of the invention is that a conveyor beam of any desired shape can be obtained in an easy and fast way.Type: GrantFiled: July 3, 2013Date of Patent: January 19, 2016Assignee: FlexLink ABInventors: Magnus Askerdal, Marko Salmi
-
Publication number: 20150377885Abstract: This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favourable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favourable change or starts to show an unfavourable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS.Type: ApplicationFiled: January 22, 2014Publication date: December 31, 2015Applicant: TURUN PATENTTITOIMISTO OYInventors: Mikael MAKSIMOW, Marko SALMI, Markku JALKANEN, Sirpa JALKANEN
-
Publication number: 20150136571Abstract: Conveyor beam for a conveyor system, comprising a plurality of connector elements and at least two conveyor beam elements, where the connector element comprises a central portion, two outer portions and two peripherally grooves extending peripherally around the connector element between the central portion and the outer portions, where the connector element is provided with a first inserting position in which the connector element is inserted between two conveyor beam elements with the first outer portion positioned in a channel of a first conveyor beam element and the second outer portion positioned in a channel of a second conveyor beam elements, and a second arresting position, in which the connector element locks the conveyor beam elements together to form the conveyor beam. The advantage of the invention is that a conveyor beam of any desired shape can be obtained in an easy and fast way.Type: ApplicationFiled: July 3, 2013Publication date: May 21, 2015Inventors: Magnus Askerdal, Marko Salmi
-
Patent number: 8975081Abstract: The invention concerns a method for monitoring the development of a disease in a patient, and for assessing the efficacy of a therapy influencing on the CD73 level or activity in the patient, in particular a cytokine therapy or a statin therapy. CD73 in a tissue fluid drawn from the patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.Type: GrantFiled: February 25, 2013Date of Patent: March 10, 2015Assignee: Faron Pharmaceuticals OyInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen, Mikael Maksimow
-
Publication number: 20140294760Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.Type: ApplicationFiled: March 25, 2014Publication date: October 2, 2014Applicant: FARON PHARMACEUTICALS OYInventors: Sirpa JALKANEN, Marko SALMI, Markku JALKANEN
-
Patent number: 8722045Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.Type: GrantFiled: April 6, 2010Date of Patent: May 13, 2014Assignee: Faron Pharmaceuticals OyInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Publication number: 20120115815Abstract: This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.Type: ApplicationFiled: January 19, 2012Publication date: May 10, 2012Applicant: BIOTIE THERAPIES CORP.Inventors: Sirpa JALKANEN, Marko SALMI, Markku JALKANEN
-
Patent number: 8119651Abstract: This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.Type: GrantFiled: April 1, 2008Date of Patent: February 21, 2012Assignee: Biotie Therapies Corp.Inventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Publication number: 20120027770Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.Type: ApplicationFiled: April 6, 2010Publication date: February 2, 2012Applicant: FARON PHARMACEUTICALS OYInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Patent number: 7910097Abstract: A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.Type: GrantFiled: March 5, 2008Date of Patent: March 22, 2011Assignee: Faron Pharmaceuticals OyInventors: Sirpa Jalkanen, Heikki Irjala, Marko Salmi
-
Publication number: 20110038922Abstract: This invention relates to small interfering RNAs (siRNAs) that down regulates the expression of vascular adhesion protein 1 (VAP-1) for prevention or treatment of a disease or disorder that benefits from the inhibition or down regulation of VAP-1. Pharmaceutical compositions comprising said siRNAs in combination with pharmaceutically acceptable carriers are also included. Furthermore, the invention concerns expression vectors comprising nucleic acids encoding the siRNA duplexes or the antisense strands of said duplexes in a manner which allows expression of said siRNA duplexes or antisense strands within a mammalian cell. Pharmaceutical compositions comprising said expression vectors in combination with pharmaceutically acceptable carriers are also included.Type: ApplicationFiled: June 12, 2006Publication date: February 17, 2011Applicant: FARON PHARMACEUTICALS OY (A FINNISH COMPANY)Inventors: Sirpa Jalkanen, Markku Jalkanen, Marko Salmi
-
Publication number: 20100310579Abstract: The invention concerns a method for inhibiting angiogenesis or for treating or preventing cancer or cancer metastasis in an individual. The method is based on the administration of an agent capable of counteracting the influence of or for down-regulating the expression of the vascular adhesion protein 1 (VAP-I). The inhibition of the catalytic activity of VAP-I is especially desirable for inhibiting angiogenesis and for treating or preventing of cancer or cancer metastasis.Type: ApplicationFiled: October 15, 2008Publication date: December 9, 2010Applicant: Faron Ventures OyInventors: Marko Salmi, Sirpa Jalkanen
-
Publication number: 20100209942Abstract: The invention concerns a method for monitoring the development of a disease in a patient, or for assessing the efficacy of a cytokine therapy or a statin therapy in a patient, in which methods CD73 in a tissue fluid drawn from said patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.Type: ApplicationFiled: October 15, 2008Publication date: August 19, 2010Applicant: FARON PHARMACEUTICALS OY a Finnish companyInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Publication number: 20080267958Abstract: A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.Type: ApplicationFiled: March 5, 2008Publication date: October 30, 2008Inventors: Sirpa Jalkanen, Heikki Irjala, Marko Salmi
-
Publication number: 20080213176Abstract: This invention relates to a diagnostic compositions for targeting an amine oxidase enzyme in vivo, said composition comprising a labelled peptide having the capability to bind to said enzyme. Further, the invention concerns a pharmaceutical composition for use to modulate the activity of an amine oxidase enzyme, said composition comprising a peptide having the capability to bind to said enzyme, wherein said peptide further is conjugated to a therapeutically active agent. Still further, the invention concerns a novel peptide and its uses, especially as VAP-1 inhibitor.Type: ApplicationFiled: May 4, 2006Publication date: September 4, 2008Inventors: Sirpa Jalkanen, Marko Salmi
-
Publication number: 20080206313Abstract: This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.Type: ApplicationFiled: April 1, 2008Publication date: August 28, 2008Applicant: FARON PHARMACEUTICALS OYInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Patent number: 7354577Abstract: A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.Type: GrantFiled: January 8, 2003Date of Patent: April 8, 2008Assignee: Faron Pharmaceuticals OyInventors: Sirpa Jalkanen, Heikki Irjala, Marko Salmi
-
Publication number: 20070191408Abstract: The present invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual in which an effective amount of an amine oxidase enzyme inhibitor is administered to the individual. The invention also relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual in which a vitamin B1, its derivative, its precursor or metabolite is administered to the individual. In addition, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, as well as a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.Type: ApplicationFiled: July 19, 2006Publication date: August 16, 2007Applicant: Faron Pharmaceuticals OyInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen